The German LIPLEG study, recently published in The Lancet, is the first large randomized controlled trial of liposuction for lipedema. It is real progress: for the first time, high-quality evidence shows surgery relieves lipedema pain far better than compression and lymphatic drainage alone.

But if you are seeking insurance coverage in the United States, our advice may surprise you. Lipedema Coverage Connection (LCC) does not recommend citing LIPLEG in your coverage request or appeal. Here is why, and what actually wins coverage.

What LIPLEG found

Liposuction cut leg pain dramatically: 68% of women who had surgery reported a meaningful drop in leg pain after 12 months, compared with 8% of women who stayed on conservative therapy.

The trial ran at 11 centers in Germany. It enrolled women with stage I, II or III lipedema whose average leg pain was at least 4 on a 0–10 scale. Every participant first completed up to seven months of conservative therapy. Then 410 women were randomized: 278 to liposuction (up to four procedures) and 132 to conservative therapy alone.

Key results at 12 months:

• Pain: average leg pain fell from 6.2 to 2.6 after liposuction. Without surgery, it rose slightly, from 6.3 to 6.6.
• Every stage benefited: the results held for stage I, II and III lipedema.
• Quality of life: physical health scores improved far more often after surgery, and mental health scores improved as well.
• Compression continues: about 7 in 10 surgical patients kept up conservative therapy after their final procedure. Surgery treats the disease; it does not end the need for compression.

The study also reported a trade-off. Nearly half (47%) of surgical patients had at least one adverse event, versus 21% in the conservative group. Serious events occurred in about 8% versus 3%. Common complications included drops in hemoglobin and surgical-site infections, though German experts interviewed by Medscape described most events as mild to moderate.

Two limits are worth knowing. Results so far cover only 12 months; 36-month follow-up is still to come. And participants were women who wanted liposuction from the start, which may have shaped who enrolled.

What LIPLEG didn’t measure

LIPLEG measured leg pain, and only leg pain. It did not look at pain or function in the hips, buttocks or abdomen, and it did not study skin excisions. Those are exactly the areas U.S. insurers most often refuse to cover.

This is not a criticism of the researchers; they answered the question they set out to answer. But for U.S. patients, a landmark study focused on the legs risks reinforcing a narrative we have spent years pushing back on.

The U.S. Standard of Care has the same blind spot. Relying on older German research, it states that lipedema spares the trunk, and it emphasizes joint problems in the legs. Insurers and external reviewers have cited it dozens of times to uphold denials on the grounds that lipedema only affects the legs.

U.S. coverage already goes further than Germany’s

LIPLEG helped persuade Germany to cover liposuction for lipedema through its statutory health insurance in 2026. Coverage now extends to all three stages; before, it was generally limited to stage III. But it applies to the legs and arms only, and it comes with conditions: at least six months of conservative treatment without enough relief, a quality-assurance guideline, and extra criteria for patients with obesity.

In the U.S., coverage is broader and has been for years:

• Blue Cross Blue Shield: 24 of the 29 BCBS plans have had lipedema surgery policies for three years or more that cover the legs and arms (Minnesota covers the legs only).
• Aetna, Anthem, UnitedHealthcare and Cigna: these major insurers, each of which faced lawsuits over lipedema care, cover the arms and legs plus the hips and buttocks. All but Cigna also cover the abdomen.

Much of the BCBS progress came from educating medical directors and legal counsel about those lawsuits, not from new research.

Gaps remain. A little more than a third of the BCBS plans that cover lipedema surgery exclude liposuction of the hips, buttocks or abdomen. Their stated reason is not that the surgery is cosmetic, but that it is investigational. In our experience, these insurers recognize that lipedema affects more than the limbs; their resistance tends to reflect a belief that women can lose weight in these areas, or concern about the cost of additional procedures.

Why citing LIPLEG could backfire

We do not expect insurers to roll back coverage of the limbs, although a few have stopped covering the trunk. A trial that measured only leg pain, and reported adverse events in nearly half of surgical patients, hands a reviewer two easy arguments: only the legs are proven, and surgery is risky. Insurers may well start citing LIPLEG to deny care. That is why, as with the Standard of Care, LCC advises members not to cite it.

The real barrier is payment, not proof

Germany shows that coverage on paper does not guarantee care. Only hospitals and practices that meet the new quality-assurance guideline may provide the surgery. And according to Tobias Hirsch, a German expert interviewed by Medscape, “the reimbursement structure is so poor” that very few facilities in the statutory system offer it at all.

U.S. patients face the same problem in a different form. The insurers that were sued have not rolled back coverage. Instead, low payment to surgeons makes covered care hard to reach. Four issues drive this:

1. The billing code doesn’t fit the surgery. Liposuction CPT codes were built for small skin-flap procedures, not lipedema operations that run four hours or more. Payment will not reflect the work until the American Society of Plastic Surgeons proposes a lipedema-specific CPT code. That is unlikely soon: most society members are university-based and focus on cancer and other reconstructive codes they use in their own practices.
2. A new diagnosis code won’t fix it. The upcoming ICD-12 code for lipedema is welcome recognition, much like LIPLEG. But lipedema surgery has been covered under broader diagnosis codes for years. Diagnosis was never the barrier; the billing code is.
3. Single case agreements are under strain. A small number of out-of-network surgeons billed excessive units, against LCC’s advice. That has contributed to a national problem with out-of-network single case agreements that we have been working to resolve for a year.
4. Network contracts are the durable fix. The most reliable path is finding strong in-network surgeons and carving lipedema rates into their contracts. That has now happened in Michigan, Maryland/DC, Florida and Illinois.

This is the fight LCC and our members take on every day: getting insurers to pay surgeons enough to keep lipedema surgery accessible.

How LCC wins coverage beyond the limbs

LCC has secured coverage of the hips, buttocks and abdomen for over a thousand women, directly or on appeal. We have also won coverage of panniculectomy and abdominoplasty hundreds of times as an alternative to liposuction of the abdomen, and persuaded some BCBS plans to revise their policies to cover more than the limbs.

The hips, buttocks and abdomen

Since the Standard of Care was published, we no longer use the word “trunk” in any materials LCC members submit, and we advise plastic surgeons to do the same. We name the hips, buttocks and abdomen instead.

When we appeal a denial for these areas, we win by focusing on:

• FDA rules for investigational devices
• Affordable Care Act standards for additional review
• Standards of practice
• The medical necessity of removing diseased tissue
• Photos of treated and untreated areas

For years, LCC has also had independent physical and occupational therapists measure members’ function in the hips, buttocks and abdomen.

Skin excisions

Women with stage 2 lipedema and above often need skin excisions, yet about half of BCBS plans don’t explicitly mention them. Some of those plans cover excisions anyway; others treat them as cosmetic. Germany doesn’t cover skin removal at all, calling it “skin tightening.”

That label misses the point. Removing excess skin after lipedema surgery is reconstructive surgery related to a disease. Loose skin can interfere with compression and cause infections, and LIPLEG itself showed that most patients still rely on conservative therapy after surgery.

Some reviewers have denied excisions as too invasive. We have won many of these appeals by focusing on reconstructive policies and regulations, on the fact that every insurer requires compression, and on insurers whose decisions are outliers among their peers.

What would actually help U.S. patients

Research that supports U.S. coverage should be done in the U.S., where far more women are already getting treatment. The most useful studies would:

• Compare pain in the hips, buttocks and abdomen between women whose surgery was covered and women whose insurance refused it.
• Repeat functional measurements after surgery, building on the physical and occupational therapy assessments LCC members already complete, to show the improvement.
• Document the safety of skin excisions, showing that infection and complication rates are low and in line with cosmetic body-contouring surgery.

The Lipedema Foundation should make pain and function in these areas, and the safety of skin excisions, a research priority. Rather than waiting for U.S. surgeons to propose studies, it should engage them directly. We also hope future revisions to the U.S. Standard of Care will address lipedema in the hips, buttocks and abdomen, as well as skin excisions, which its surgery section does not mention.

Research alone won’t protect access, though. LCC has worked with media outlets in several states. A more coordinated effort among lipedema organizations, surgeons and even social media voices to address payment would protect coverage for women with lipedema, and for their daughters, for years to come.

The bottom line

LIPLEG is a welcome milestone that confirms what women with lipedema already know: surgery works. But in the U.S., coverage is won through policy, regulation and fair payment, not through one study of leg pain. Don’t let your insurer deny coverage or payment of your hips, buttocks, abdomen or skin excisions. LCC can help you build a request or an appeal with arguments that win.

Sources

• Michael van den Heuvel, “Lipedema: Liposuction Cuts Pain, but at What Cost?” Medscape, September 18, 2026 (translated from Medscape’s German edition)
• LIPLEG trial results, The Lancet, 2026
• LIPLEG study protocol, Trials, 2021 — defines leg pain as the trial’s primary outcome